Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib monotherapy in chronic lymphocytic leukemia
NL-OMON59294Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of acalabrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (3 cohorts), sponsored by AstraZeneca. Primary endpoint: Safety and tolerability. Started Mar 2020; status: completed.
02
Drugs
acalabrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on NL-OMON59294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59294.